Literature DB >> 8143658

Susceptibility of ponies to infection with Streptococcus pneumoniae (capsular type 3)

A S Blunden1, D Hannant, G Livesay, J A Mumford.   

Abstract

Welsh Mountain ponies were inoculated with an isolate of Streptococcus pneumoniae, SPE 1618 (capsular type 3) recovered from the equine respiratory tract: 10 ml of a suspension of 10(8) or 10(9) cfu/ml were instilled intratracheally. Fever was observed after either dose but the greater concentration also produced coughing, ocular and nasal discharge, depression and enlargement of submandibular lymph nodes. Cytological evidence of infection was also observed in tracheal washings during the first week after inoculation and corresponded with isolation of S. pneumoniae from the washes. Morbid anatomical and histopathological examinations of selected animals revealed focal pneumonia affecting the ventral lung, especially the cardiac area and accessory lobe, with a propensity to affect the right lung. S. pneumoniae was isolated directly in pure culture from these lesions or was demonstrable by immunostaining of macrophages bearing specific capsular type 3 antigen. By 10 days after inoculation, the ponies were healthy and had developed antibodies to S. pneumoniae. S. pneumoniae was therefore a primary pathogen in the horse under the conditions of the challenge.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8143658     DOI: 10.1111/j.2042-3306.1994.tb04325.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  2 in total

1.  Molecular characterization of equine isolates of Streptococcus pneumoniae: natural disruption of genes encoding the virulence factors pneumolysin and autolysin.

Authors:  A M Whatmore; S J King; N C Doherty; D Sturgeon; N Chanter; C G Dowson
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

2.  Association between respiratory disease and bacterial and viral infections in British racehorses.

Authors:  J L N Wood; J R Newton; N Chanter; J A Mumford
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.